The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy.
Cutaneous melanoma
Immune checkpoint inhibitors
Ipilimumab
Nivolumab
Pan-immune-inflammation value
Pembrolizumab
Systemic immune-inflammation index
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
17
11
2021
accepted:
01
12
2021
pubmed:
11
1
2022
medline:
28
9
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
To evaluate the pan-immune-inflammation value (PIV) and systemic immune-inflammation index (SII) in patients with cutaneous melanoma (CM) under immune checkpoint inhibitor (ICI) therapy. PIV and SII were calculated before the start of ICI therapy and at time of progression/death in patients with metastatic CM (stage III/IV). Sex-age-matched CM patients in stage I/II and healthy subjects (HC) served as controls. The median PIV of stage III/IV patients was significantly (P = 0.0011) higher than in stage I/II patients and HC. SII was significantly (P = 0.00044) lower in HC than in CM patients. At baseline, PIV and SII did significantly correlate with lactate dehydrogenase (P = 0.045/0.017). However, ROC curve statistics revealed that SII and PIV were not significantly associated with clinical parameters, including best response to ICI treatment (P = 0.87/0.64), progression-free survival (P = 0.73/0.91), and melanoma-specific survival (P = 0.13/0.17). Moreover, there were no significant changes of PIV and SII from baseline to progression/death (P = 0.38/0.52). Even though both immune-inflammation biomarkers showed some power to differentiate between CM stages and HC, respectively, PIV and SII seem not to be significant predictors for clinical outcome measures of CM patients under ICI therapy.
Identifiants
pubmed: 35006344
doi: 10.1007/s00432-021-03878-y
pii: 10.1007/s00432-021-03878-y
pmc: PMC9508007
doi:
Substances chimiques
Biomarkers
0
Immune Checkpoint Inhibitors
0
Immunologic Factors
0
Nivolumab
31YO63LBSN
Lactate Dehydrogenases
EC 1.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3103-3108Informations de copyright
© 2022. The Author(s).
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12
pubmed: 24793958
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
Int J Clin Oncol. 2019 Oct;24(10):1301-1310
pubmed: 31073814
Transl Oncol. 2017 Oct;10(5):719-725
pubmed: 28710916
Curr Pharm Des. 2015;21(21):3032-40
pubmed: 26004407
J Cancer. 2018 Sep 7;9(18):3295-3302
pubmed: 30271489
J Invest Dermatol. 2016 Jun;136(6):1161-1171
pubmed: 26902923
Ann Surg Oncol. 2018 Oct;25(11):3341-3349
pubmed: 30066226
Sci Rep. 2018 Jul 12;8(1):10566
pubmed: 30002404
Cancer Immunol Immunother. 2020 Apr;69(4):559-568
pubmed: 31974724
Oncotarget. 2018 Jan 3;9(15):12452-12470
pubmed: 29552325
Oncotarget. 2017 Jun 29;8(43):75381-75388
pubmed: 29088873
Clin Transl Oncol. 2021 Feb;23(2):311-317
pubmed: 32562197
Target Oncol. 2021 Jul;16(4):529-536
pubmed: 34076798
Front Oncol. 2021 May 20;11:639085
pubmed: 34094921
Cancer Treat Rev. 2015 Dec;41(10):971-8
pubmed: 26481060
Br J Dermatol. 2016 Jan;174(1):146-51
pubmed: 26343230
J Dtsch Dermatol Ges. 2016 Jul;14(7):662-81
pubmed: 27373241
J Surg Oncol. 2018 Nov;118(6):915-921
pubmed: 30196539
Br J Cancer. 2020 Aug;123(3):403-409
pubmed: 32424148
J Eur Acad Dermatol Venereol. 2017 May;31(5):815-820
pubmed: 28045207
Oncotarget. 2018 Oct 19;9(82):35293-35299
pubmed: 30450158
Radiol Oncol. 2021 May 31;55(3):347-353
pubmed: 34051707